On the other hand, when fewer than 3% of tumor-reactive T cells, fewer than 2 × 109 tumor-reactive T cells, or low tumor-induced IFN-γ release were observed, patients underwent poor clinical responses (135). This evidence concerns the gene IFNG and neoplasm.